Bristol-Myers Squibb Co () said on Monday it bought privately held drug developer Cardioxyl Pharmaceuticals Inc in a deal worth up to $2.07 billion, to gain access to a heart failure treatment.
Bristol-Myers said Cardioxyl's CXL-1427, which is in mid-stage...